The aim of the study was to evaluate the ovulation stimulatory effect of a combination of clomiphene citrate (CC) and tamoxifen (T) or letrozole (L) in CC-resistant polycystic ovary syndrome women.
Introduction
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder affecting women of reproductive age. Some 20% of women will have polycystic ovaries on an ultrasound scan and around 7% of women have the additional clinical or biochemical features of PCOS. PCOS is of clinical and public health importance as it has significant and diverse clinical implications including reproductive, metabolic, and psychological features. PCOS is a heterogenous condition, and risk factors include genetics, metabolic profiles, and the in-utero environment; thus, clinical and research agendas are broad and involve many disciplines [1] [2] [3] .
Clomiphene citrate (CC) is a nonsteroidal selective estrogen receptor modulator that acts primarily by binding with estrogen receptors at the hypothalamus. This competitive inhibition results in a perceived drop of circulating estrogen to the hypothalamus and eventually leads to increased gonadotrophin secretion and subsequent induction of ovulation. Although CC results in ovulation in most patients, the pregnancy rates are disappointing [4] [5] [6] .
Clomiphene resistance, defined as failure to ovulate after receiving 150 mg of CC daily for 5 days per cycle, for at least three cycles, is common and occurs in B15-40% in women with PCOS. Insulin resistance, hyperandrogenemia, and obesity represent the major factors involved in CC resistance; they avert the ovaries from responding to raised endogenous follicle stimulating hormone (FSH) levels following CC therapy. A genetic predisposition is also suggested [7, 8] .
Aromatase is a microsomal member of the cytochrome P450 hemoprotein-containing enzyme complex superfamily (P450arom, the product of the CYP19 gene) that synthesizes estrogens by catalyzing three consecutive hydroxylation reactions converting C19 androgens to aromatic C18 estrogenic steroids. Aromatase is expressed in a tissue-specific manner, and its activity can be demonstrated in several tissues, including the ovaries, brain, placenta, adipose tissue, muscle, liver, breast, and estrogen-dependent breast cancer tissue [9] .
Estradiol is produced by the ovarian granulosa cells and exerts a negative feedback effect on FSH release from the pituitary gland. When aromatization of androgens to estrogens is inhibited, a reduction of circulating estrogens causes release of the hypothalamic-pituitary axis from estrogenic negative feedback, and FSH secretion is increased. The resultant stimulatory effect on the growth of ovarian follicles and aromatase inhibition increase intraovarian androgens and seem to augment follicular sensitivity to FSH [10, 11] .
Tamoxifen (TMX), a selective estrogen receptor modulator, has been the standard treatment for estrogenreceptor-positive breast cancer patients in both the adjuvant and metastatic setting. TMX itself is considered a prodrug that is converted into many metabolites. The metabolites with the highest therapeutic activity are 4hydroxytamoxifen and N-desmethyl-4-hydroxytamoxifen (endoxifen), binding 100-fold more potent to the oestrogen receptor than TMX itself. TMX is metabolized by cytochrome P450 enzymes, in which the formation of endoxifen predominantly depends on CYP2D6 [12] [13] [14] .
The current prospective comparative study aimed to evaluate the ovulation stimulatory effect of the combination of CC and TMX or letrozole in CC-resistant PCOS women.
Patients and methods
The present study was conducted at the Department of Obstetrics and Gynecology, Benha University Hospital, from January 2011 to June 2013. The study aimed to recruit infertile couples in whom the wives had menstrual disturbances such as oligomenorrhea or regular menstrual cycles without ovulation (anovulation was confirmed on the basis of progesterone levels on day 21 of their cycles) in addition to other criteria of PCOS diagnosed on the basis of the Rotterdam criteria, including biochemical hyperandrogenemia (serum total testosterone level 4 0.8 ng/ml) and polycystic ovaries (412 follicles in the 2-9 mm range and/or an ovarian volume410 ml per ovary by vaginal ultrasound) [15, 16] .
Patients with endocrinpathy, current or previous pregnancy within 1 year of enrollment, or who were using hormonal contraception within the last 6 months before inclusion in the study were excluded.
Apart from PCOS, all enrolled women had to have undergone a normal transvaginal ultrasonographic (TVU) examination and hysterosalpingogram and their husbands' seminal examination had to be in the acceptable ranges, so that the only reason for their infertility was ovulatory dysfunction. All enrolled women must have been on CC for at least 6 months and should have failed to respond to therapy and to form a dominant follicle.
After approval of the study protocol by the local ethical committee and obtaining fully informed patient consent, 120 PCOS women fulfilling the inclusion criteria were enrolled. TVU was repeated on day 2 or 3 before commencement of the drug regimen; if follicles larger than 2 cm were detected, therapy was not started.
All patients underwent anthropometric measurements, including body height and weight, and BMI was calculated as body weight in kg divided by square of body height in meters [17] . Obesity grades were defined as per WHO guidelines [18] as follows: BMIo24.9, average; 25 to <30 kg/m 2 , overweight; BMI Z30 to 35 kg/m 2 , obese; and BMIZ35 kg/m 2 , morbidly obese. Fasting blood samples were collected from enrolled women for determination of the hormone profiles, including estimation of serum levels of FSH, luteinizing hormone, estradiol, progesterone, testosterone, and sex hormone binding globulin by radioimmunoassay using commercial enzymatic kits (Diagnostic Systems Laboratories; Texas, USA). Free androgen index was calculated as (testosterone/sex hormone binding globulin) Â 100.
Thereafter, women were randomly divided into three equal study groups, using sealed envelopes. All enrolled patients received CC at a dose of 100 mg daily as a fixed therapy in addition to either tamoxifen citrate at 20 mg twice daily (group T) or letrozole at 5 or 7.5 mg once daily (groups L5 and L7.5, respectively) for 5 days. In patients with oligomenorrhea, the medication started after induction of bleeding with progesterone, and for those patients with regular cycles the medications were started from day 2 or 3 of the cycle. Vaginal ultrasound was performed on day 11 of the cycle to evaluate the growth of follicles, and Gonal-f (rFSH, Puregon; NV Organon, OSS, the Netherlands) was prescribed to complete the follicle growth.
Ovulation was monitored by measuring the serum concentration of progesterone on day 21 of the menstrual cycle, and serum progesterone level of at least 25 nmol/l was used to indicate ovulation, which was confirmed using TVU for evident ovulation with a dominant follicle size greater than 18 mm. Presence of these follicles was considered successful ovulation. Timed intercourse was assigned and pregnancy was diagnosed chemically and confirmed by TVU, and the pregnancy rate was calculated.
Statistical analysis
Data were presented as mean ± SD, ranges, numbers, and ratios. Results were analyzed using Wilcoxon ranked test for unrelated data (Z-test) and the w 2 -test. Statistical analysis was conducted using the SPSS (version 15, 2006; SPSS Inc., Chicago, Illinois, USA) for Windows statistical package. P values less than 0.05 were considered statistically significant.
Results
The study included 120 PCOS women with a mean age of 26.4 ± 3.1 years (19-35 years). Fifty-six women (46.7%) were morbidly obese with BMI at least 35 kg/m 2 , 45 women (37.5%) were obese with BMI in the range of 30-35 kg/m 2 , and 19 women (15.8%) were overweight with BMI less than 30 kg/m 2 . The mean BMI of the enrolled women was 34.6 ± 3 (28.1-39.7 kg/m 2 ). Twentyone women had regular menstruation, whereas the remaining women had menstrual irregularities. Forty women were primary infertile, whereas 80 women were secondary infertile, with the mean duration of infertility of 3.4 ± 1.3 (range: 1-6 years). Seventy women were nullipara, 33 women had one previous pregnancy, and 17 women had two previous pregnancies. Thirty-one women had undergone a previous miscarriage. There was a nonsignificant (P40.05) difference between the studied groups concerning demographic, infertility, and obstetric data, as shown in Table 1 . The baseline hormonal profile showed nonsignificant (P40.05) difference between the studied groups (Table 2 ).
Both lines of therapy successfully induced ovulation, with nonsignificant (P40.05) difference between TMX and letrozole as regards the number of applied trials, number of ovulatory trials, and frequency of pregnancy; the results, however, were in favor of TMX (Tables 3 and 4 ).
Over the 3-month study period, 314 trials were conducted for a median number of 0.87 trial/patient. The total number of trials was 111 (0.925 trial/patient) in group L5, 105 trials (0.875 trial/patient) in group T, and 98 trials (0.817 trial/patient) in group L7.5. The proportion of trials to achieve ovulation in group L5 was significantly higher compared with that of group T (P 1 = 0.014) and group L7.5 (P 2 o0.001), with significantly higher proportion in group T compared with group L7.5 (P 1 = 0.008) ( Tables 3 and 4 and Fig. 1 ).
Out of the 314 trials, ovulation was achieved in 256 cycles for a total ovulatory success rate of 81.5%. Ovulation was achieved in 88, 83, and 85 trials in groups T, L5, and L7.5, respectively, for an ovulatory success rate of 83.8, 74.8 and 86.7%, respectively. The frequency of successful ovulatory trials in group L5 was significantly lower compared with that of group T (P 1 = 0.018) and group L7.5 (P 2 = 0.008), with nonsignificantly lower frequency of successful ovulatory trials in group T compared with group L7.5 (P 1 40.05) (Tables 3 and 4 and Fig. 1 ).
From all ovulatory cycles, 50 women became pregnant, resulting in a total pregnancy rate of 19.5% cycles and 41.7% patients; in group T, 17 women became pregnant, yielding a pregnancy rate of 19.3 and 42.5%; in group L5, 12 women became pregnant, yielding a pregnancy rate of 14.5 and 30%; and in group L7.5, 21 women became pregnant, resulting in a pregnancy rate of 24.7 and 52.5% of cycles and patients, respectively. The frequency of pregnancy as outcome/patient was significantly lower in group L5 compared with group T (P 1 = 0.047) and group L7.5 (P 2 = 0.012), with nonsignificantly lower pregnancy rate in group T compared with group L7.5 (P 1 40.05) (Tables 3 and 4 and Fig. 2 ). Details of trial outcomes are shown in Table 5 .
Discussion
Of all PCOS-associated problems, the major one is infertility secondary to ovulatory failure; the current study reported an overall ovulatory success rate of 85.3 per trial using antiestrogen therapy, irrespective of drug or dose used, among women who were CC resistant. Both TMX and letrozole induced ovulation, with success rates showing a nonsignificant difference between the two drugs. However, the ovulatory success rate was significantly higher with letrozole at a daily dose of 7.5 mg compared with a daily dose of 5 mg. Moreover, TMX induced a significantly higher ovulatory success rate with significant reduction in the number of trials to induce ovulation compared with letrozole 5 mg, with nonsignificantly lower rates compared with letrozole at 7.5 mg daily dose.
These findings point to the fact that antiestrogen therapy in combination with CC is an effective management policy for CC-resistant PCOS cases and that either TMX or letrozole at a daily dose of 7.5 mg is equally effective. These data support previous reports in the literature, where Nardo [19] compared CC (50 mg/day for days [2] [3] [4] [5] [6] with TXM (20 mg/day for days 2-5), with doubling of the dose in case ovulation failed to occur, and found that the overall ovulation rate was significantly higher with TMX compared with CC (62.2 vs. 47.2%), but with statistically nonsignificant higher pregnancy rate per ovulatory cycle. They concluded that TMX is a safe and effective agent, and a suitable alternative to CC for anovulatory infertility in women with PCOS. Wang et al. [20] compared ovarian stimulation with TMX (40 mg/day for 7 days) versus CC (100 mg/day for 5 days) and found that TMX-treated women had fewer follicles greater than 14 mm compared with clomiphene-treated patients. However, a significantly increased endometrial thickness and pregnancy rate, decreased early miscarriage rate, and thus improved ongoing pregnancy rate were noted in TMX-treated patients. Zakherah et al. [21] compared the efficacy of CC plus TMX with that of laparoscopic ovarian drilling (LOD) in clomiphene-resistant women with PCOS and found that CC plus TMX was as effective as LOD, with no significant differences regarding rates of ovulation, pregnancy, or live births; however, the mean endometrium thickness was significantly greater on the day of human chorionic gonadotropin administration with CC plus TMX.
Dhaliwal et al. [22] tried to evaluate the role of TMX in women with anovulatory infertility and reported a pregnancy rate of 38.8 and 28.5% in women with PCOS and women with CC failure, respectively, and concluded that TMX is a good alternative to clomiphene in women with PCOS and CC resistance. Nahid and Sirous [23] found that the effect of letrozole compared with CC on stimulation of ovulation was almost the same, with comparable pregnancy rates, but CC caused endometrial thinning more often than did letrozole.
Recently, Franik et al. [24] conducted a search of published randomized controlled trials to evaluate the effectiveness and safety of aromatase inhibitors in subfertile women with anovulatory PCOS and found that the pregnancy rate was higher in the letrozole group compared with CC, followed by timed intercourse (14 studies) or intrauterine insemination (IUI) (three studies).
With regard to the used doses of both drugs, in group T, TMX was given at a dose of 20 mg twice daily for a total daily dose of 40 mg and the reported successful ovulation rate was 83.8% with a pregnancy rate of 42.5% per patient. These figures were superior to those reported by Nardo [19] , who reported an overall ovulation of 62.2% with TMX at 20 mg daily. Dhaliwal et al. [22] reported a pregnancy rate of 14.94 and 33.68% in women using TMX 40 and 80 mg, respectively. In L5 and L7.5 groups of the current study, letrozole was used at a dose of 5 and 7.5 mg, respectively, and the reported successful ovulation rates were 74.8 and 86.7%, with a pregnancy rate of 30 and 52.5% per patient in L5 and L7.5 groups, respectively. These figures were consistent with and superior to that reported by Rahmani et al. [25] , who used letrozole at doses of 2.5, 5, and 7.5 mg and reported that follicles occurred in 22.9, 42.1, and 85.18% of cycles, and the pregnancy rate was 14.58, 28.94, and 33.33%, respectively.
In support of the obtained results, Badawy and Gibreal [26] compared CC and TMX as a first-line therapy for ovulation induction in women with PCOS and found that the number of stimulated follicles reaching at least 16 mm in diameter was significantly more in the CC group; the endometrium at the time of hCG administration was significantly thicker in the TMX group and ovulation occurred in 64 and 51.6% of patients in the CC and TMX groups, respectively.
Abu Hashim et al. [27] conducted a PubMed search for the trials on the role of LOD in the management of PCOS and found that LOD, whether unilateral or bilateral, is a beneficial second-line treatment in infertile women with CC-resistant PCOS. However, recent evidence suggests that relatively novel oral methods of ovulation induction -for example, CC plus metformin, CC plus TMX, rosiglitazone plus CC, and aromatase inhibitors -represent a successful alternative to LOD in CC-resistant PCOS.
Hajishafiha et al. [28] proposed that in PCOS patients resistant to clomiphene and letrozole used as single agents, a combination of the two drugs can be administered before starting more aggressive treatment that may have severe complications, or before surgery; this combination may also be used as a first-line therapy to induce ovulation in severe cases of PCOS to save time Group T Group L5 Group L7.5
Woman
Frequency of pregnancy recorded in the studied groups. and expense. Pourmatroud et al. [29] assessed the effectiveness of TXM administration with letrozole in the context of IUI cycles and documented that, in addition to the efficacy of TXM in coadministration with CC, it has promising effects with letrozole in the induction of ovulation cycles with or without IUI.
Conclusion
In CC-resistant PCOS women, letrozole successfully induced dose-dependent ovulation and pregnancy rate per cycle and per patient. TMX also successfully induced ovulation and pregnancy rates with a frequency significantly higher than that of letrozole at 5 mg/day and nonsignificantly lower than that of letrozole at 7.5 mg/day. Combination of CC with either TMX or letrozole at a dose of 7.5 mg/day is equally effective and could be prescribed according to patients' condition and physician preference.
